Kamada Ltd. - Ordinary Shares (KMDA) is currently showing a slightly bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: There is a mild positive lean in the higher-value headlines, though the setup is not strong enough to call decisively bullish.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
63/100
Slightly Bullish
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$7.15
Trend Context
Mixed / range
Latest briefing
What's happening with KMDA
globenewswire.com13 Jul 2026
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com1 Jun 2026
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced FDA approval of the Company's new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. RFFIT is the gold standard neutralizing test used to measure the level of rabies-neutralizing antibodies.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
